Global GM1 Gangliosidosis Treatment Market Overview:
Global GM1 Gangliosidosis Treatment Market is expected to grow at a significant rate during the forecast period 2026-2035, with 2025 as the base year.
Global GM1 Gangliosidosis Treatment Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of GM1 Gangliosidosis Treatment involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the GM1 Gangliosidosis Treatment Market:
The GM1 Gangliosidosis Treatment Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for GM1 Gangliosidosis Treatment Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study GM1 Gangliosidosis Treatment Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, GM1 Gangliosidosis Treatment market has been segmented into:
LYS-GM101
PBGM01
AXO-AAV-GM1
By Application, GM1 Gangliosidosis Treatment market has been segmented into:
Type 1 GM1 Gangliosidosis
Type 2 GM1 Gangliosidosis
and Type 3 GM1 Gangliosidosis
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The GM1 Gangliosidosis Treatment market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the GM1 Gangliosidosis Treatment market.
Top Key Players Covered in GM1 Gangliosidosis Treatment market are:
Axovant Gene Therapies Ltd
Passage Bio and Lysogene.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: GM1 Gangliosidosis Treatment Market by Type
4.1 GM1 Gangliosidosis Treatment Market Snapshot and Growth Engine
4.2 GM1 Gangliosidosis Treatment Market Overview
4.3 LYS-GM101
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 LYS-GM101: Geographic Segmentation Analysis
4.4 PBGM01
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 PBGM01: Geographic Segmentation Analysis
4.5 AXO-AAV-GM1
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 AXO-AAV-GM1: Geographic Segmentation Analysis
Chapter 5: GM1 Gangliosidosis Treatment Market by Application
5.1 GM1 Gangliosidosis Treatment Market Snapshot and Growth Engine
5.2 GM1 Gangliosidosis Treatment Market Overview
5.3 Type 1 GM1 Gangliosidosis
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Type 1 GM1 Gangliosidosis: Geographic Segmentation Analysis
5.4 Type 2 GM1 Gangliosidosis
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Type 2 GM1 Gangliosidosis: Geographic Segmentation Analysis
5.5 and Type 3 GM1 Gangliosidosis
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 and Type 3 GM1 Gangliosidosis: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 GM1 Gangliosidosis Treatment Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 AXOVANT GENE THERAPIES LTD
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 PASSAGE BIO AND LYSOGENE.
Chapter 7: Global GM1 Gangliosidosis Treatment Market By Region
7.1 Overview
7.2. North America GM1 Gangliosidosis Treatment Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 LYS-GM101
7.2.4.2 PBGM01
7.2.4.3 AXO-AAV-GM1
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Type 1 GM1 Gangliosidosis
7.2.5.2 Type 2 GM1 Gangliosidosis
7.2.5.3 and Type 3 GM1 Gangliosidosis
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe GM1 Gangliosidosis Treatment Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 LYS-GM101
7.3.4.2 PBGM01
7.3.4.3 AXO-AAV-GM1
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Type 1 GM1 Gangliosidosis
7.3.5.2 Type 2 GM1 Gangliosidosis
7.3.5.3 and Type 3 GM1 Gangliosidosis
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe GM1 Gangliosidosis Treatment Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 LYS-GM101
7.4.4.2 PBGM01
7.4.4.3 AXO-AAV-GM1
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Type 1 GM1 Gangliosidosis
7.4.5.2 Type 2 GM1 Gangliosidosis
7.4.5.3 and Type 3 GM1 Gangliosidosis
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific GM1 Gangliosidosis Treatment Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 LYS-GM101
7.5.4.2 PBGM01
7.5.4.3 AXO-AAV-GM1
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Type 1 GM1 Gangliosidosis
7.5.5.2 Type 2 GM1 Gangliosidosis
7.5.5.3 and Type 3 GM1 Gangliosidosis
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa GM1 Gangliosidosis Treatment Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 LYS-GM101
7.6.4.2 PBGM01
7.6.4.3 AXO-AAV-GM1
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Type 1 GM1 Gangliosidosis
7.6.5.2 Type 2 GM1 Gangliosidosis
7.6.5.3 and Type 3 GM1 Gangliosidosis
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America GM1 Gangliosidosis Treatment Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 LYS-GM101
7.7.4.2 PBGM01
7.7.4.3 AXO-AAV-GM1
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Type 1 GM1 Gangliosidosis
7.7.5.2 Type 2 GM1 Gangliosidosis
7.7.5.3 and Type 3 GM1 Gangliosidosis
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
GM1 Gangliosidosis Treatment Scope:
|
Report Data
|
GM1 Gangliosidosis Treatment Market
|
|
GM1 Gangliosidosis Treatment Market Size in 2025
|
USD XX million
|
|
GM1 Gangliosidosis Treatment CAGR 2025 - 2032
|
XX%
|
|
GM1 Gangliosidosis Treatment Base Year
|
2024
|
|
GM1 Gangliosidosis Treatment Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Axovant Gene Therapies Ltd, Passage Bio and Lysogene..
|
|
Key Segments
|
By Type
LYS-GM101
PBGM01
AXO-AAV-GM1
By Applications
Type 1 GM1 Gangliosidosis
Type 2 GM1 Gangliosidosis
and Type 3 GM1 Gangliosidosis
|
